Compare Alphabet Inc Class A (GOOGL) vs Moderna, Inc. (MRNA) Price & Performance

Alphabet Inc Class ATrade

Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Alphabet Inc Class A vs Moderna, Inc. — how do they compare? Alphabet Inc Class A trades at $354.44 (market cap $4.52T), while Moderna, Inc. trades at $62.92 (market cap $27.09B). The key difference: Alphabet Inc Class A is far larger — about 166.9× Moderna, Inc.'s market cap, and Alphabet Inc Class A pays a 0.24% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.

	GOOGL	MRNA
Market Cap	$4.52T	$27.09B
Sector	Media	Health
52-Week High	$402.62	$81.80
52-Week Low	$182.97	$22.36
Enterprise Value	$4.49T	$23.19B
Dividend Yield	0.24%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alphabet Inc Class A

Alphabet (GOOGL) trades at $356.14, down 0.94% on the day, with strong technical support at $355 and resistance at $375. The stock shows bullish momentum in moving averages while oscillators remain neutral. Recent earnings consistently beat expectations, with Q1 2026 EPS of $5.11 significantly exceeding the $2.64 forecast. Revenue growth accelerated to $402.84 billion in 2025, with net income margins expanding to 32.8%.

Alphabet presents a compelling investment case with 85% analyst buy ratings and a $431.78 consensus price target representing 21% upside. Strong AI integration, YouTube price increases, and cloud partnerships drive growth, though regulatory scrutiny and tech sector volatility remain key risks. The company's robust cash flow generation and strategic investments position it well for sustained outperformance.

Moderna, Inc.

Moderna (MRNA) trades at $64.11, down 4.94% over 24 hours, with a bullish technical outlook but mixed fundamentals. The company reported a net loss of -$2.82B in 2025 despite beating EPS estimates in recent quarters. Recent news highlights progress in oncology trials and an EU RSV vaccine contract, fueling investor optimism about pipeline expansion beyond COVID-19 vaccines.

Outlook: Long-term growth depends on successful pipeline commercialization, but high cash burn and negative margins pose risks. Analyst consensus is cautious with a $49 price target, suggesting 23.6% downside. Investors should weigh clinical successes against persistent profitability challenges.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

GOOGL

Google updates Vids with AI avatars and Gemini Omni for custom video creation.TechCrunch · 5 hours agoBullish Edge AI software market to hit $8.89B by 2031, growing at 24.4% CAGR driven by real-time AI demand.Marketsandmarkets™ · 5 hours agoBullish Analyst predicts 70% cloud growth for Alphabet ahead of strong Q2 earnings reportBenzinga · 6 hours agoBullish View details →

MRNA

Arbutus sues Pfizer/BioNTech over LNP patents, gets $178M from Moderna, plans $230M share buybackGlobeNewsWire · 12 hours agoNeutral Moderna's Q2 report expected uneventful; key focus on COVID vaccine demand and Phase III melanoma data.Proactive Investors · 2 days agoNeutral View details →

About Alphabet Inc Class A

Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.